Toronto and Munich-based Wayland Group (formerly Maricann) (CSE:WAYL) (OTCQB:MRRCF) signed a joint venture agreement with CBD Italian Factory S.S., an Italian cannabis production company in the Group San Martino.
Wayland believes that JVs are key to gaining first mover advantage there. The joint venture brings them local expertise and existing infrastructure in Piedmont, Italy. CBD Italian Factory S.S. and San Martino Group bring mass-scale agricultural skills and local sustainable practices. The JV will be a split of 50.1% for Wayland and 49.9% for CBD Italian Factory, with Massimiliano Umberto Signorini as CEO.
“We are now well positioned in the Italian market for CBD and potential THC production,” said Ben Ward, Chief Executive Officer of Wayland.
Part of the JV is a relationship with the University of Eastern Piedmont, which will develop a research center for the betterment of cannabis products for humans and animals. Initial research will focus on producing high CBD content for medical purposes, which will lead to further studies into high THC content, and medical uses.
Wayland Group will also license VESIsorb® technology to the JV with immediate import of products that contain, leading predictable, consistent, rapid onset absorption. VESIsorb® has multiple applications in beverage, edibles, capsules and transdermal products.
Wayland is a vertically integrated producer and distributor of cannabis for medical purposes.
Learn more about other exciting cannabis-based pharmaceutical products in the Cannin Report. Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll help you determine which cannabis companies to invest in.
Source Wayland press release